AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31121013 — intervention group
Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r)
Number of subjects: 0
Study 31121013 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study 31070574 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaster fixation
Number of subjects: 38
Study 31070574 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wire transfixation
Number of subjects: 38
Study 29018070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE) for 1-2 hours via the portal vein before implantation
Number of subjects: 46
Study 29018070 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold storage (control)
Number of subjects: 46
Study 29018070 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE
Number of subjects: 46
Study 26251958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 μg
Number of subjects: 35
Study 26251958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg
Number of subjects: 35
Study 26251958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26251958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 35
Study 23320428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional consultation by dietitians
Number of subjects: 537
Study 23320428 — intervention group
Group type: COMPARATOR
Intervention: No nutritional consultation (Control)
Number of subjects: 537
Study 21280077 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg
Number of subjects: 1155
Study 21280077 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg
Number of subjects: 1155
Study 21280077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (20 mg and 40 mg)
Number of subjects: 1155
Study 19878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2766
Study 19878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily as tolerated)
Number of subjects: 2766
Study 19878986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2766
Study 16861405 — intervention group
Group type: EXPERIMENTAL
Intervention: RA plus clonidine 1 microg/kg as the initial loading dose followed by 1 microg.kg(‐1).h(‐1)
Number of subjects: 80
Study 16861405 — intervention group
Group type: COMPARATOR
Intervention: RA plus placebo
Number of subjects: 80
Study 12611558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenugreek seed powder
Number of subjects: 0
Study 10390546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vgamma9/Vdelta2 T lymphocytes from cerebrospinal fluid (CSF) of TBM patients
Number of subjects: 0
Study 10390546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vgamma9/Vdelta2 T cells from CSF of TBM children
Number of subjects: 0
Study 10390546 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro expansion of Vgamma9/Vdelta2 T cells from CSF and peripheral blood of TBM patients
Number of subjects: 0
Study 10390546 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of ex vivo unstimulated Vgamma9/Vdelta2 T cells in CSF of TBM patients
Number of subjects: 0
Study 10390546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vdelta2 CDR3 TCR analysis of remaining Vdelta2 cells in CSF of TBM patients
Number of subjects: 0
Study 8522715 — intervention group
Group type: EXPERIMENTAL
Intervention: E4031
Number of subjects: 0
Study 8522715 — intervention group
Group type: EXPERIMENTAL
Intervention: dofetilide
Number of subjects: 0
Study 8522715 — intervention group
Group type: EXPERIMENTAL
Intervention: MS551
Number of subjects: 0
Study 8522715 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 0
Study 2051152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60
Study 2051152 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 2051152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2051152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 60
Study 6297870 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with 6000 rad
Number of subjects: 142
Study 6297870 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 142
Study 30887761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 80
Study 30887761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 80
Study 30703441 — intervention group
Group type: EXPERIMENTAL
Intervention: CyclASol 0.05%
Number of subjects: 207
Study 30703441 — intervention group
Group type: EXPERIMENTAL
Intervention: CyclASol 0.1%
Number of subjects: 207
Study 30703441 — intervention group
Group type: EXPERIMENTAL
Intervention: Restasis
Number of subjects: 207
Study 30703441 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 207
Study 28968167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 265
Study 28968167 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 265
Study 28968167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy in T790M mutation-positive patients
Number of subjects: 265
Study 28968167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy in T790M mutation-negative patients
Number of subjects: 265
Study 28968167 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy in T790M mutation-negative patients
Number of subjects: 265
Study 24690021 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 12
Study 24690021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23408495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (CBZ) 100 mg dose as partial replacement of morning dose
Number of subjects: 113
Study 23408495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (CBZ) 100 mg dose
Number of subjects: 113
Study 21069518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 30
Study 21069518 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 30
Study 21069518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 30
Study 19394661 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/d
Number of subjects: 27
Study 19394661 — intervention group
Group type: COMPARATOR
Intervention: glyburide 10 mg/d
Number of subjects: 27
Study 17076326 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond control (SE)
Number of subjects: 0
Study 17076326 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Protect Bond control (PB)
Number of subjects: 0
Study 17076326 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer[SE]/Adhesive[PB]
Number of subjects: 0
Study 17076326 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer[PB]/Adhesive[SE]
Number of subjects: 0
Study 15658652 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection (SFI) plus conventional therapy (mainly glucocorticoids)
Number of subjects: 80
Study 15658652 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (mainly glucocorticoids)
Number of subjects: 80
Study 11178762 — intervention group
Group type: COMPARATOR
Intervention: Repair of incidental defects during laparoscopic TAPP repair (Control group: 16 patients)
Number of subjects: 32
Study 11178762 — intervention group
Group type: EXPERIMENTAL
Intervention: No repair of incidental defects during laparoscopic TAPP repair (Trial group: 21 patients)
Number of subjects: 32
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg bromazepam
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 376
Study 9603590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 376
Study 9603590 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 376
Study 7825081 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacuation under systemic analgesia (fentanyl and midazolam)
Number of subjects: 142
Study 7825081 — intervention group
Group type: COMPARATOR
Intervention: Evacuation under general anaesthesia
Number of subjects: 142
Study 3137608 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg diazepam
Number of subjects: 28
Study 3137608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diazepam
Number of subjects: 28
Study 3137608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 28
Study 3137608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30623096 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 150, 300, or 450 mg co‐mixed with rHuPH20
Number of subjects: 60
Study 30623096 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 300 mg + rHuPH20
Number of subjects: 60
Study 30623096 — intervention group
Group type: COMPARATOR
Intervention: bococizumab 300 mg alone
Number of subjects: 60
Study 26943336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-augmented reinforcement with large-pore polypropylene mesh (Ultrapro, width 7.5 cm)
Number of subjects: 120
Study 26943336 — intervention group
Group type: COMPARATOR
Intervention: Conventional closure
Number of subjects: 120
Study 26943336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-augmented reinforcement
Number of subjects: 120
Study 25716365 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 47
Study 25716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Test foods (15 Southeast Asian foods)
Number of subjects: 47
Study 24385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics and health conditions (younger age, increased education, White race)
Number of subjects: 2782
Study 24385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, diabetes, suspected clinical depression
Number of subjects: 2782
Study 24385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected clinical depression
Number of subjects: 2782
Study 24385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and history of stroke
Number of subjects: 2782
Study 20463587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen (clear liquid diet, 4 L of PEG, and 1 or 2 NaP boosters)
Number of subjects: 40
Study 20463587 — intervention group
Group type: COMPARATOR
Intervention: Modified regimen (1 or 2 PEG boosters, 4 senna tablets, and a low-residue diet)
Number of subjects: 40
Study 20463587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen
Number of subjects: 40
Study 20463587 — intervention group
Group type: COMPARATOR
Intervention: Modified regimen
Number of subjects: 40
Study 20463587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 40
Study 19356075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (single oral dose)
Number of subjects: 87
Study 19356075 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 genotypes
Number of subjects: 87
Study 19356075 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 haplotypes
Number of subjects: 87
Study 19356075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine PBMC pharmacokinetics
Number of subjects: 87
Study 17069542 — intervention group
Group type: EXPERIMENTAL
Intervention: CX516
Number of subjects: 49
Study 17069542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 12552363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate (7.5 mg) plus ibuprofen (200 mg)
Number of subjects: 72
Study 12552363 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 72
Study 12552363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11180025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 5 mg
Number of subjects: 15
Study 11180025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 15
Study 11180025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 15
Study 11180025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 20 mg
Number of subjects: 15
Study 11180025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9365149 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg by mouth twice a day for eight weeks
Number of subjects: 36
Study 9365149 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 36
Study 9365149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1506656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.66 units/min)
Number of subjects: 33
Study 1506656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 33
Study 1506656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin plus Ketanserin
Number of subjects: 33
Study 7309410 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall associates produced five minutes later
Number of subjects: 0
Study 7309410 — intervention group
Group type: COMPARATOR
Intervention: Recall associates produced 24 hours later
Number of subjects: 0
Study 7309410 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial association task with emotional words
Number of subjects: 0
Study 31037562 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily for 8 weeks
Number of subjects: 17
Study 31037562 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg daily for 8 weeks
Number of subjects: 17
Study 31037562 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 17
Study 25418187 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 925
Study 25418187 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 925
Study 25418187 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 925
Study 23663001 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 1478
Study 23663001 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 1478
Study 23663001 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 1478
Study 23663001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1478
Study 21896132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid containing oil-in-water emulsion applied once daily in the evening for 90 days
Number of subjects: 120
Study 21896132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19219442 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) in group A
Number of subjects: 75
Study 19219442 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of local anaesthetic (1 mL lidocaine) combined with peppering technique in group B
Number of subjects: 75
Study 19219442 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) and peppering technique in group C
Number of subjects: 75
Study 19219442 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group C to group A
Number of subjects: 75
Study 19219442 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group C to group B
Number of subjects: 75
Study 19219442 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS pain measurement at 6 months for all groups
Number of subjects: 75
Study 17849682 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioe Cavity Care by LG Care, Korea
Number of subjects: 3
Study 17849682 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total by Colgate‐Palmolive, Thailand
Number of subjects: 3
Study 17849682 — intervention group
Group type: COMPARATOR
Intervention: Vicco by Vicco Labs, India
Number of subjects: 3
Study 16565915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Re‐entry Module (CRM)
Number of subjects: 96
Study 16565915 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 96
Study 14523786 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered recombinant interleukin-2 (rIL-2)
Number of subjects: 0
Study 14523786 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy without rIL-2 (Control)
Number of subjects: 0
Study 9890319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Number of subjects: 152
Study 9890319 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Number of subjects: 152
Study 9890319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ceftazidime treatment
Number of subjects: 152
Study 9890319 — intervention group
Group type: COMPARATOR
Intervention: Continuous ceftazidime treatment
Number of subjects: 152
Study 9890319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with glycopeptide and ceftazidime
Number of subjects: 152
Study 9890319 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with glycopeptide and ceftazidime
Number of subjects: 152
Study 9890319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent and continuous treatment
Number of subjects: 152
Study 7752906 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1,200 mg daily for 12 weeks
Number of subjects: 20
Study 7752906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7752906 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 20
Study 2267193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 36
Study 2267193 — intervention group
Group type: COMPARATOR
Intervention: Fenactil, Torecan, Aviomarin, Primperan
Number of subjects: 36
Study 2267193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 179
Study 7011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride plus hydrochlorothiazide
Number of subjects: 179
Study 7011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 179
Study 31866419 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerful Tools for Caregivers (PTC) intervention
Number of subjects: 60
Study 31866419 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study 31129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 359
Study 31129681 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during pregnancy
Number of subjects: 359
Study 31129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal non-iron-deficiency anemia (NIDA)
Number of subjects: 359
Study 26099028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis
Number of subjects: 11
Study 26099028 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral untreated flanks)
Number of subjects: 11
Study 23756830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue condition
Number of subjects: 10
Study 23756830 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study 21858548 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental Zn per day)
Number of subjects: 90
Study 21858548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18269665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to one side of the operation area for 7 days
Number of subjects: 20
Study 18269665 — intervention group
Group type: COMPARATOR
Intervention: Control (no LLLT applied)
Number of subjects: 20
Study 16439173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1.5 microg/kg
Number of subjects: 6
Study 16439173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3.0 microg/kg
Number of subjects: 6
Study 14669620 — intervention group
Group type: EXPERIMENTAL
Intervention: roncoleukin
Number of subjects: 100
Study 14669620 — intervention group
Group type: EXPERIMENTAL
Intervention: betaleukin
Number of subjects: 100
Study 11323998 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 0
Study 11323998 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide eugenol
Number of subjects: 0
Study 8781939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine alone
Number of subjects: 160
Study 8781939 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine plus absolute alcohol
Number of subjects: 160
Study 1626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Number of subjects: 11
Study 1626795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Number of subjects: 11
Study 1626795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered into the nose when B was administered into the bronchi and vice versa)
Number of subjects: 11
Study 6359846 — intervention group
Group type: EXPERIMENTAL
Intervention: pirbuterol (n = 10)
Number of subjects: 20